Outreach Breathes Hope Into Atlanta Communities

BY MELINDA TANZOLA
Elsevier Global Medical News

ATLANTA — Not one more life, asthma education and screening events at Atlanta churches. Michael Stader, RRT, is part of the respiratory team that conducts asthma education and screening events at Atlanta churches.

New Year, Same Story: CMS Will Cut Pay 4.6% in ’07

BY ALICIA AULT
Elsevier Global Medical News

In a not unexpected, but definitely unwelcome move, the Centers for Medicare and Medicaid Services has announced that it will cut physician pay by 4.6% for 2007.

The federal health program said the scheduled decrease in physician fees is based partly on the fact that spending for physicians’ services rose by 8.3% in 2005, with 7.3% of that rise due to growth in the volume and intensity of physician services.

Physician organizations blame the hit on the sustainable growth rate (SGR). If Medicare spending on physicians increases more than the SGR, CMS must cut physician fees; lower spending means higher rates for physicians.

But errors made in setting the SGR in 1998 and 1999 have led to annual proposed cutbacks and yearly congressional bailouts. Last year, for instance, medical organizations successfully lobbied Congress to block a proposed 4.4% cut for 2006, but because legislators did not increase fees, payments essentially were frozen at the 2005 rate.

This year, physician groups such as the American College of Chest Physicians again say that they will urge Congress to stop the fee cut and repair the SGR.

“The ACCP’s Government Relations Committee agrees with the MedPAC recommendation that Congress eliminate the SGR and adopt the same approach, based on the Medicare Economic Index (MEI), for physician payment updates that is used for other Medicare providers,” said Dr. Lawrence C. Moht, FCCP chair of the committee. “Such an approach would ensure that physician payments reflect the cost of practice.”

“We’ve been strong along by Congress for years now on

IOM: Time to Wake Up to Sleep Disorders

BY DOUG BRUNK
Elsevier Global Medical News

It’s time for physicians and the public alike to wake up to the staggering impact of sleep disorders, a new report from the Institute of Medicine charges.

An estimated 50-70 million Americans suffer from chronic sleep disorders such as insomnia, sleep apnea, and restless legs syndrome, yet the vast majority “go unrecognized because nobody’s asking patients about them,” Dr. Harvey R. Colten, who chaired the committee that assembled the report, said in an interview. “Even when they do ask, they’re not following up on the problem and dealing with it either directly or by referral. That’s a major issue for the practitioner as well as for the medical educator.”

Titled “Sleep Disorders and Sleep Deprivation: An Unmet Public Health Problem,” the wide-ranging report noted that fatigue alone costs an estimated $150 billion a year in lost productivity and mishaps, and another $48 billion in medical costs related to motor vehicle accidents that involve drowsy drivers. Data from the 1990s suggest that sleep disorders themselves cost an estimated $15.8 billion in medical costs, a figure the committee believes is conservative.

“What we found was that sleep disorders are extremely common,” said Dr. Allan I. Pack, one of the report’s committee members. “They obviously have an impact not only on sleep and behavior, but in cardiovascular disease and metabolic effects. There really is an unmet public
Sleep Medicine Report Debuts
Wake up from page 1

The report is “an important next step in the evolution of sleep medicine from its beginnings to its teenage years, and into its adulthood,” said Dr. Charles W. Atwood Jr., professor of the division of pulmonary, allergic and critical care medicine at the University of Pittsburgh Medical Center. Dr. Atwood is also the Chair of the ACCP Sleep Institute.

Sleep medicine “has been growing steadily as a clinical activity, but what has not kept up with it is the realization that it’s becoming a full-fledged academic activity,” he observed. “Medical schools and academic medical centers really need to take notice of it and do what they can to foster the next generation of researchers who are going to make new discoveries about sleep and to train the next generation of clinicians who are going to take care of patients with sleep disorders.”

Physicians can do their part, he added, by asking their patients simple questions about sleep during routine office visits. He offered the following question as an example: Do you feel like you have enough alertness to get you through the day in an adequate fashion, or are you too sleepy? “If they seem too sleepy or if they have to fight off sleep at inappropriate times on a regular basis, that’s a problem,” Dr. Atwood said. The physician “should follow that up with questions about how much sleep the patient gets [and] if the patient has been told that he or she has excessive snoring or stops breathing at night. That can lead into a number of different directions. But if they ask about getting enough sleep and about potential sleep apnea, that’s a good start.”

The 386-page report calls for AASM accreditation of the nation’s sleep disorder centers and labs for sleep-related breathing disorders. Dr. Pack estimated that only 30%-35% of the nation’s sleep disorder centers and labs currently hold such credentials. “We shouldn’t really have sleep labs where you just go in and get a [sleep] test,” he said. “It’s really about management of patients and improving outcomes. An important part of the accreditation procedure should be looking at the outcomes of management: How well are you doing in terms of management? There are some obvious metrics in that regard, like what your [continuous positive airway pressure] compliance data are on. That could be brought in to make sure that people are focusing on the outcomes and not just on the diagnosis.”

Dr. Atwood considers accreditation important, because “it lends credibility to the effort that you’re doing locally, and I think it provides some degree of quality assurance that you’re using practices that are generally accepted as good.”

The report also recommends that every academic medical center build an interdisciplinary sleep program that emphasizes long-term clinical care, training, and research. Academic medical centers “should take a major responsibility, not only for clinical care, but they should take a major responsibility for education.” Dr. Pack said. “We think it’s very important that they’re involved in educating primary care physicians. Primary care providers need to be educated in sleep disorders: the differential, how you recognize them, and so on.”

Other key strategies in the report’s executive summary include the following:

► Increase awareness of the burden of sleep loss and sleep disorders among the general public by developing a multimedia, comprehensive education campaign on the health and economic impact of sleep loss and sleep disorders.
► Establish the workforce required to meet the clinical and scientific demands of the field. In 2004, only 534 people in the United States received doctorate degrees in somnology or sleep medicine.
► Develop and validate new and existing diagnostic and therapeutic technologies.

One focus “is a call for research and validation of at-home monitoring so that this bottleneck of sleep labs isn’t the sole means for making a definitive diagnosis of a sleep disorder,” said Dr. Colten. “That’s a pressing need.”

A national research network that connects individual investigators, research programs, and research centers.

The full text of “Sleep Disorders and Sleep Deprivation: An Unmet Public Health Problem,” is available online at http://nap.edu.

DATA WATCH

Top 10 Drugs Prescribed by Pulmonologists in 2005

<table>
<thead>
<tr>
<th>Drug</th>
<th>Millions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Advair Diskus</td>
<td>1.048</td>
</tr>
<tr>
<td>Singular</td>
<td>0.839</td>
</tr>
<tr>
<td>Spiriva</td>
<td>0.762</td>
</tr>
<tr>
<td>Combivent</td>
<td>0.679</td>
</tr>
<tr>
<td>Lipitor</td>
<td>0.533</td>
</tr>
<tr>
<td>Flonase</td>
<td>0.360</td>
</tr>
<tr>
<td>Levaquin</td>
<td>0.294</td>
</tr>
<tr>
<td>Ambien</td>
<td>0.281</td>
</tr>
<tr>
<td>Nurofen</td>
<td>0.265</td>
</tr>
<tr>
<td>Zolmitram Z-Pak</td>
<td>0.263</td>
</tr>
</tbody>
</table>

Note: Estimated data based on prescription drugs dispensed by retail pharmacies throughout the United States.

Source: Verispan
Screening Program Reaches Out

Atlanta • from page 1

This community-based combination of education and participation is the crux of the “Not One More Life” program, and the results of the approach thus far have been very encouraging. A Not One More Life visit to a church begins with the initial contact, logistics, and setup arranged by the program director. The program is a two-person team consisting of one or two physicians (usually a pulmonologist or allergist) and two or three respiratory therapists, in addition to asthma educators and other volunteers, then visits the church.

The program opens with a presentation on asthma and lung disease, with an emphasis on practical knowledge that educators attendees on what they should expect from good health care—and in particular from good asthma control.

Participants then fill out a symptom-based questionnaire drawn from the Juniper model, undergo spirometry to assess lung function, and sit down with a physician to discuss the results of the questionnaire and spirometry reading.

In contrast with a health fair, in which about half of attendees may allow themselves to undergo some type of testing, 82%-85% of participants at the Not One More Life sessions will submit to testing. “We think that’s because of the unique trust relationship that is fostered in this setting,” Dr. Graham explained. “We are inviting people to participate, who participate by helping set up and encouraging people to participate.”

After undergoing testing, individuals with signs of asthma or other lung disease are then provided with a report to give to their primary care providers. Those without a primary care physician, or those requiring a specialist, are referred to a network of providers. Though most participants have some insurance coverage, pro bono care is available.

“We know we’re capturing an important population, because 60% of the people who attend our sessions have either abnormal symptoms and/or abnormal lung function, while only 20% of them have self-reported asthma,” said Dr. Graham.

The program also has revealed a disconnect in some individuals between reported symptoms and lung function test results. Between 15% and 18% of participants report no symptoms, despite having measurable abnormal lung function.

Over the past 3 years, more than 1,500 participants have attended more than 40 sessions, resulting in detection of abnormal lung function and/or symptoms in 1,200 people. Although the program was originally intended for children, it has since expanded to encompass all adults at all stages of life, and has served participants from age 4 to 86 years.

Unlike other programs or health fairs that have only single encounters with people, Not One More Life has a nurse outcome manager who places serial follow-up phone calls at 1, 3, and 6 months after the sessions to find out whether participants have visited a physician and are receiving treatment.

According to these follow-ups, 97% of individuals identified at the sessions as having abnormal lung function go on to visit a physician for further evaluation and treatment. This high success rate shows how effective such a comprehensive community-based program can be, the program’s leaders say.

“We’ve had some astounding success stories—people calling us up, saying, ‘oh my God, I didn’t know I could feel this good!’ ” Dr. Graham added. In addition to asthma, Not One More Life screening has detected emphysema, sarcoidosis, chronic bronchitis, and pulmonary complications of HIV.

As the final and most expensive portion of the program, Not One More Life provides Internet-ready computers to small- and medium-sized churches. In Atlanta, only 30% of African American homes have Internet access, compared with 70% of white homes, Dr. Graham said.

By providing these computers, the program enables churches to set up a health kiosk where individuals can learn about different health topics. The program Web site, www.notonemorelife.org, contains information on the Not One More Life program, links to other health Web sites, and a directory of free and reduced fee clinics.

When Not One More Life was first proposed in mid-2000, Dr. Graham and associates lacked the funds necessary to put their concept into action. So they began to pursue funding through industry sponsors. They have since received financial support from pharmaceutical companies to carry out their mission.

In December 2005, Not One More Life gained nonprofit 501(c)(3) status, which allowed the program to receive contributions directly.

It is largely volunteer based, with all clinicians giving their time without compensation. Currently, the only paid individuals are the program coordinator, the nurse outcome manager, a grant writer, and a director of development. The program’s outreach component earned Dr. Graham THE CHEST Foundation’s Governor’s Community Service Award in 2004. That success may soon be replicated beyond Not One More Life’s current settings.

Dr. Graham said he hopes to expand the reach of Not One More Life beyond asthma screening in African American churches in Atlanta. Not One More Life has visited other faith-based communities such as mosques, Southern Baptist churches, and synagogues.

Outside Atlanta, Dr. Graham has made contact with interested persons in other major U.S. cities, and he hopes to be able to spread the concept to these other areas. For those interested in starting a community-based health education and screening program, Dr. Graham has provided some perspectives based on lessons learned over the 5-year history of Not One More Life. (See box.)

Given the positive outcomes with Not One More Life, Dr. Graham believes the model could be useful in educating and screening people for a variety of disorders, including obesity, diabetes, and hypertension. Such community-based approaches may provide a real solution for addressing unmet health care needs one individual at a time, he said.

Medicare Reimbursement to Drop

CMS • from page 1

The bill introduced last year by Rep. Nancy Johnson (R-Conn.) is a good starting point for negotiations, Mr. Hope said. The American Medical Association supported Rep. Johnson’s bill, and will urge Congress to stop the cuts, an AMA spokeswoman said.

In a statement, Dr. Duane Cady, AMA chair, said that the 2007 reduction “is just the tip of the iceberg.” Over 9 years, the pay cuts will total 34%, while practice costs will increase 22%, Dr. Cady said. An AMA survey found that in 2004, 73% of physicians will defer buying new equipment and 65% will put off purchases of new information technology—at a time when practices are being asked to convert to electronic health records and collect more data on quality and health outcomes.

“You can’t expect doctors to move toward electronic health records facing that kind of hit,” Mr. Hope agreed. Dr. Fields said that physicians may stop taking new Medicare patients, or, even worse, may have to close their practices. “When the overhead is greater than the payment, there won’t be any access,” he said, adding that closures will impact private-pay patients also.

Even CMS agreed that the practice environment is getting harder. “Physicians may find it very difficult to invest in an area where 73% of physicians will defer buying new equipment and 65% will put off purchases of new information technology—at a time when practices are being asked to convert to electronic health records and collect more data on quality and health outcomes.”

“ ‘It’s always next year, next year, next year, and next year never seems to show up.’ DR. FIELDS

Medicare Payment Advisory Commission. The fastest-growing components of physician services included imaging (16% growth), laboratory and other tests (11% growth), and procedures (9% growth), according to the letter. Procedures accounted for 26% of Medicare spending, compared with 14% for imaging and 12% for laboratory and other tests.

An increase in evaluation and management services accounted for the largest portion of the 8.5% overall growth in physician services, but the 11% growth rate—7%—was less than for the other services.

Dr. Cady said that it’s not surprising that physician services are growing faster because patients are living longer with chronic conditions and more emphasis is being placed on preventive care.

Organizing an Outreach Program

► Learn about the community. Be willing to listen and learn from the community leaders rather than having a missionary approach. A transactional approach, in which there is a partner ship within the community, is more likely to succeed, Dr. Graham said. “People don’t want to be saved—people want to be empowered,” he explained.

► Show respect for the community. In working with churches, realize that pastors know what works in their communities. The members of the church place their trust in pastors, and if the pastor trusts you, that trust of the people from the community will be carried over to you as well.

► Be flexible in your scheduling. Timing can be an important determinant of a session’s success. It is important to identify when a session would be most beneficial. For churches, Saturday or Sunday after services often works, and can result in a spillover effect from other activities going on. In fact, some churches may have a luncheon or dinner in conjunction with the event.

► Engage the participants. Many participants say that they have never had a chance to sit down with a doctor one on one. This individual attention can make a difference for many people.

► Address the whole needs of the people. In many cases, health care encompasses social and cultural issues as well. People may have a “crisis view” of health care, in which they only attend to their health when a problem arises. In these situations, it is important to explain the importance of preventative care.
The angiogenesis inhibitor bevacizumab should get a thumbs-up or -down from the Food and Drug Administration sometime this year or early next year for use in the treatment of non-squamous non–small cell lung cancer. F. Hoffman–La Roche Ltd. and Genentech Inc., manufacturers of bevacizumab (Avastin), asked the Food and Drug Administration last month to approve the antiangiogenic agent—a monoclonal antibody—for use in combination with platinum-based chemotherapy (carboplatin plus paclitaxel) for previously untreated patients with advanced non–small cell lung cancer (NSCLC), the most common form of lung cancer.

The companies requested a “priority review” for the treatment; if granted, the agent would be reviewed within 6 months, about half the usual amount of time.

Their submission to the Food and Drug Administration is based on results of a randomized, controlled phase III trial of patients with locally advanced, metastatic or recurrent NSCLC, which was presented at last year’s annual meeting of the American Society of Clinical Oncology.

At that time, presenters reported that patients receiving bevacizumab plus chemotherapy had a 30% improvement in overall survival, compared with patients who received chemotherapy alone.

According to the final analysis from Roche and Genentech, patients treated with bevacizumab plus chemotherapy had an overall median survival of 12.3 months, compared with 10.3 months for the control group.

That difference translates into a 25% improvement in overall survival.

Less than 5% of patients with advanced NSCLC survive for 5 years, and most die within 12 months.

In the United States, non–small cell lung cancer accounts for 87% of all lung cancers, according to company reports.

The drug was approved in 2004 as a front-line treatment for patients with metastatic colon cancer, based similarly on trial data showing that the drug extended patients’ lives by about 5 months when given in combination with standard chemotherapy agents.

According to the Food and Drug Administration, bevacizumab is the first product to be approved that works by preventing angiogenesis—a strategy first proposed more than 30 years ago.

It is believed to target and inhibit vascular endothelial growth factor, thus preventing the growth of blood vessels that feed tumors, the Food and Drug Administration has said.
Late-Onset Anaphylaxis to Omalizumab Reported

By Patrice Wendling
Elsevier Global Medical News

Miami Beach — Two patients developed anaphylaxis to the popular allergic asthma medication omalizumab after months of successful treatment, Dr. Kursteen Price reported in a poster at the annual meeting of the American Academy of Allergy, Asthma, and Immunology.

This is the first report of late-onset anaphylaxis to the humanized monoclonal anti-immunoglobulin E (IgE) antibody omalizumab (Xolair), Dr. Price said. According to the prescribing information for omalizumab, “anaphylaxis has occurred within 2 hours of the first or subsequent administration of Xolair in 3 [less than 0.1%] patients without other identifiable allergic triggers.”

“We can’t get too nonchalant about it,” Dr. Price said in an interview. “There is still the potential that patients can develop a bad reaction to the medicine. We need to look at it with caution, but I think that it’s still a very useful medication.”

According to theory, anaphylaxis to omalizumab would not occur if the drug were working. That is because omalizumab decreases IgE, which is needed to stimulate the release of histamine and other mediators during anaphylaxis. But a second mechanism has been described in mouse models in which anaphylaxis occurs through IgG mediation, said Dr. Price, an allergist in private practice in Portland, Ore. One of the patients who developed an anaphylactic reaction also was sensitive to polysorbate in eye drops, and polysorbate is present in omalizumab.

She reported on a 56-year-old woman with previously steroid-dependent asthma who developed itching and redness at the injection sites within 5 minutes of receiving her 27th bimonthly treatment with omalizumab 150 mg. Rapidly generalized itching, chest tightness, and a sense of impending doom were described by the patient, who was determined to be hypotensive and tachycardic.

The patient was given intramuscular and subcutaneous epinephrine, oxygen, a bolus of 500 mL of saline, 10 mg each of cetirizine and montelukast, and methylprednisolone (Solu-Medrol) 40 mg intramuscularly. She recovered hemodynamically within 15 minutes and was discharged hours later with no further sequelae.

One month after this anaphylactic episode, intradermal testing to omalizumab at a dilution of 1:1,000 showed a significant wheal-and-flare reaction of 10 mm/10 mm in the patient, who became symptomatic and required oral antihistamine for generalized itching.

The second case was quite different, and occurred within minutes of the 13th treatment in a woman with asthma and reflux receiving monthly treatments. There was no local injection site reaction, but the patient developed asthma, acute hives, and tightness in her throat that peaked 4 days after omalizumab therapy. She was hospitalized on the fifth day, treated, and released 2 days later. Her respiratory symptoms persisted for a month, and she required repeated treatments with epinephrine and steroids, Dr. Price said. The patient did not skin-test positive.

Novartis Pharmaceuticals, which jointly markets omalizumab with Genentech, would not confirm whether these are the first or only cases of late-onset anaphylaxis. Any spontaneous reports received in the postmarketing setting are reviewed and submitted to the Food and Drug Administration, Megan Humphrey, Novartis director of communications, said in an interview.

“The reason these patients are on Xolair is because they’re uncontrolled with other medications and continue to have allergic reactions,” she said. “There’s just no way to tell when such a person might have an allergic reaction.” In the United States, there have been more than 25,000 prescriptions for omalizumab since it was launched in June 2003, Ms. Humphrey said.

Dr. Susan M. Harding, FCCP, comments: Clinicians beware! Late-onset anaphylaxis with omalizumab is possible, even months after initiating therapy—rare, but possible. Schedule these injections early during your office time so that your patients are adequately observed and appropriate therapy is immediately available.
Inhaled AMP May Help Differentiate COPD, Asthma

It also holds promise for monitoring airway inflammation and response to treatment.

BY PATRICE WENDLING

Miami Beach — Measuring airway responsiveness to inhaled adenosine helps discriminate between a diagnosis of asthma and chronic obstructive pulmonary disease.

It’s also a valuable clinical tool for monitoring airway inflammation and response to anti-inflammatory treatment in asthma, Dr. Riccardo Polosa reported at the annual meeting of the American Academy of Allergy, Asthma, and Immunology. “AMP challenge is noninvasive, non-time consuming, low cost, has good reproducibility and patient acceptability, and safety is optimal,” he said.

Adenosine 5’-monophosphate (AMP) is a profunctor that induces bronchoconstriction in patients with inflammatory lung diseases. Response to AMP is determined by measuring the concentration of inhaled AMP causing the forced expiratory volume in 1 second (FEV1) to decrease by 20%. The exact cutoff point between normal and abnormal PC20 AMP as it is known, remains somewhat unclear. But a cutoff of 160 mg/ml has been used successfully to discriminate between asthmatics and healthy controls. AAAAI is considering standardizing and writing protocols for AMP and other indirect challenges, said session moderator Dr. Richard A. Nicklas of George Washington University, Washington, D.C.

Dr. Polosa and his colleagues at the University of Catania (Italy) have shown that airway responsiveness to inhaled AMP is closely related to the number of eosinophils in the airways of atopic patients, whereas no association was observed with methacholine, one of the most commonly used agents for assessing bronchial hyperresponsiveness (Eur. Respir. J. 2000;15:30-5).

Dr. Polosa and other researchers from the university also showed that PC20 AMP could detect inflammatory changes as early as the first week of treatment with inhaled budesonide 0.8 mg per day in mild to moderate asthmatics, while methacholine responsiveness and changes in the percentage of sputum eosinophils could be observed only by the fourth week of treatment (J. Allergy Clin. Immunol. 2002;110:855-61).

Investigators at King’s College, London, were able to demonstrate in three consecutive studies that a single dose of intranasal fluticasone propionate 100-1,000 mcg inhibited an asthmatic response to AMP in just 2 hours in patients with mild, stable asthma. A single inhalation of fluticasone 1,000 mcg had no effect on airway responsiveness to histamine (J. Allergy Clin. Immunol. 2002;110:603-6).

But when Dr. Polosa’s team performed a similarly designed randomized, double-blind study using a single inhalation of fluticasone 1,000 mcg in 14 patients with chronic obstructive pulmonary disease (COPD) and 13 with mild asthma, there was a change in response in only one of the COPD patients, he said. The experiment was repeated with similar results in 10 patients with a clear history of asthma and 10 patients with COPD and comparable fixed airway obstruction.

“This tells me very nicely that AMP challenge can be used as a strong discriminator for COPD and asthma,” he said of the unpublished findings. AMP has also been used to assess the nonsteroidal anti-inflammatory potential of several therapeutic agents including allergen immunotherapy (Clin. Exp. Allergy 2003;33:873-81), the leukotriene receptor antagonist montelukast (Am. J. Respir. Crit. Care Med. 2003;167:1232-8), and the humanized monoclonal anti-IgE antibody omaluzumab (Int. Arch. Allergy Immunol. 2006;139:122-31).

AMP may be a more useful and sensitive diagnostic tool than challenging patients with methacholine and histamine because of its unique mechanism of action, Dr. Polosa said. Histamine and methacholine have a direct spasmogenic effect on airway smooth muscle cells. AMP acts indirectly via the secondary release of mediators.

Dr. Mark Draisenfeld comments: These initial results are interesting, as at present there is no bronchodilator or bronchoconstriction provocation test that can be used to differentiate asthma and COPD. That said, larger studies are needed to confirm the findings and to standardize AMP dosing. Clinicians should be mindful that AMP challenge is not currently approved by the FDA.

Fatal Asthma Shifting to the Elderly, Declining Overall

BY PATRICE WENDLING

Miami Beach — Preliminary data from a fatal asthma registry suggest that asthma deaths continue to decline and are more common in the elderly. Dr. Carlos Camargo Jr., FCCP, said at the annual meeting of the American Academy of Allergy, Asthma, and Immunology.

Dr. Camargo and colleagues at Massachusetts General Hospital, Boston, developed a standard protocol for contacting next of kin that was submitted to institutional review boards in four states: Arkansas, Missouri, Ohio, and Massachusetts. So far they have identified 222 possible asthma fatalities, a number that is significantly lower than what would have been predicted in the late 1990s when asthma rates were climbing, he said. Estimates vary, but 5,500 asthma deaths occurred annually in the early 1990s compared with about 4,300 today.

An analysis of the first 20 deaths in Massachusetts showed that half of deaths occurred in patients older than 80 years. In almost two-thirds of the 20 fatalities, families reported that the patient who died had a history of anxiety or depression in the previous 12 months.

Most of the 20 deaths occurred in the hospital, and almost half of the deaths occurred in patients who had visited an emergency department in the previous 12 months.

“This is a different picture of asthma mortality than is generally believed,” said Dr. Camargo, chair of the academy’s asthma mortality committee.

“There have been some reports in recent years on how deaths are occurring more in the elderly, but I think it’s getting more dramatic,” he said.

The most common triggers of death were allergies or cold weather. Nearly three-fourths of the 20 patients who died had reported frequent night awakening due to their asthma prior to their deaths, consistent with a more persistent affliction. The study was funded by an unrestricted grant from GlaxoSmithKline.

The finding that many asthma deaths are occurring in the elderly has sparked efforts to create the Veterans Affairs Fatal Asthma Project, which will match cases of asthma deaths with age-matched controls living with asthma, and which aims to evaluate their health care utilization. Veterans Affairs centers in Ohio, Wisconsin, Massachusetts, and Arizona are enrolled, but Dr. Camargo urged audience members who work in the VA to contact him to broaden participation.

All of these efforts to create a national fatal asthma registry have been hampered by the Health Insurance Portability and Accountability Act and different internal review board interpretations that preclude a standardized national approach for contacting next of kin, he said (J. Asthma 2006;43:19-25).
Diabetes Risk Elevated With Smoking, Secondhand Smoke

BY MELINDA TANZOLA
Elsevier Global Medical News

Both smoking and exposure to secondhand smoke increase the risk of developing glucose intolerance, results of a prospective cohort study indicate.

Over the 15-year study period, the development of glucose intolerance was highest among smokers (22%), followed by people who had never smoked but had secondhand smoke exposure (17%), previous smokers (14%), and those who neither smoked nor had secondhand smoke exposure (11.5%).

The investigators noted that this was the first study to demonstrate that secondhand smoke is independently associated with a risk of developing glucose intolerance (BMJ 2006 April 7 [Epub doi:10.1136/bmj.38779.584028.55]).

In the Coronary Artery Risk Development in Young Adults (CARDIA) study, Dr. Thomas K. Houston of the Birmingham (Ala.) Veterans Affairs Medical Center and his associates enrolled young adults, aged 18-30, from four U.S. cities. The cohort included 1,386 smokers, 621 previous smokers, and 2,565 individuals who had never smoked; all had normal glucose tolerance at baseline. The “never smokers” included 1,452 people with secondhand smoke exposure, which was validated by a serum cotinine concentration of between 1 and 15 ng/mL.

Study participants received thorough examinations at baseline and at years 2, 5, 7, 10, and 15 that assessed medical and sociodemographic information, including economic, psychosocial, and nutritional parameters. They also were interviewed via telephone each year. By year 15, 26% of the original cohort was lost to follow-up.

After 15 years, 17% of the study population had developed glucose intolerance, which was defined as having either impaired fasting serum glucose levels—with levels greater than or equal to 100 mg/dL and less than 126 mg/dL—or diabetes, with serum glucose levels greater than or equal to 126 mg/dL.

Compared with people who had never smoked and weren’t exposed to secondhand smoke, current smokers (hazard ratio of 1.65), never smokers with secondhand smoke exposure (hazard ratio of 1.35), and previous smokers (hazard ratio of 1.17) remained at increased risk for developing glucose intolerance, after adjusting for confounding variables.

Each 10-pack-year increase in smoking increased the risk of developing glucose intolerance by 18%.

In addition to the reductions in death or respiratory failure, vaccination also significantly reduced the in-hospital risk of acute respiratory distress syndrome, sepsis syndrome, cardiac arrest, and acute renal failure. Vaccinated individuals spent a median of 2 fewer days in the hospital.

Twelve percent of the cohort had received the vaccination, 23% were unvaccinated, and the vaccination status was unknown for the remaining 63% of the patients.

The Centers for Disease Control and Prevention aims to increase the vaccination rate to 90% of older adults by 2010; the pneumococcal vaccine is recommended for persons aged 65 years and older and for younger persons with certain medical problems.
Adenotonsillectomy Linked to Improved ADHD

BY ROBERT FINN
Elsevier Global Medical News

half of all children undergoing adenotonsillectomy who were found to have attention-deficit hyperactivity disorder before the surgery no longer met the diagnostic criteria a year later, according to a prospective, controlled study. The study strengths previous observations that linked sleep-disordered breathing—a major reason for adenotonsillectomy—with attention and behavior problems.

The investigators, led by Dr. Ronald D. Chervin of the University of Michigan, Ann Arbor, acknowledged that their study does not prove cause and effect. And they also acknowledged that their study leaves an important puzzle: Although they found a strong link between adenotonsillectomy and neurobehavioral improvements (behavior, cognition, and sleepiness), they also found that sleep-disordered breathing at baseline and its subsequent improve-

THE STUDY STRENGTHENS PREVIOUS OBSERVATIONS THAT LINKED SLEEP-DISORDERED BREATHING WITH ATTENTION AND BEHAVIOR PROBLEMS.

ment did not predict either baseline neurobehavioral morbidity or its improvement in any area aside from sleepiness (Pediatr Allergy Immunol). The study involved 78 children between 1 and 13 years of age who were scheduled for adenotonsillectomy for any indication. They were compared with 27 control subjects in the same age range who were recruited from other surgical clinics. Among the children receiving adenotonsillectomy, 71 (91%) were judged to have a nocturnal upper airway obstruction. Children were excluded from the study group if they required a polysomnogram for clinical purposes, if they had a history of treatment for sleep-disordered breathing, or if they had severe medical or neurologic conditions. Children were excluded from the control group for those reasons and also if they had a history of large tonsils, frequent throat infections, adenoidectomy, or tonsillectomy.

At baseline—generally within 1 month before scheduled surgery—all children underwent full-night polysomnography, and the next day received a battery of neurobehavioral assessments including the multiple sleep latency test of daytime sleepiness and a number of neurophysiological tests. Polysomnography and neurobehavioral assessments were repeated at follow-up, about 1 year later.

Before surgery, children scheduled to undergo adenotonsillectomy were significantly worse than the control children on several measures of sleep-disordered breathing, including minimum oxygen saturation (an index of obstructive apnea), a respiratory disturbance index, and the apnea-hypopnea index (AHI). For example, the average AHI of the adenotonsillectomy children was 7.3 events per hour, compared with 1.2 events per hour for the control children.

A year later, there were no significant differences between the adenotonsillectomy and the control children on any polysomnographic measure. The average AHI of the control children remained 1.2 events per hour, while that of the adenotonsillectomy children declined to 1.1 per hour. Twenty-two (28%) of the adenotonsillectomy children had ADHD at baseline, compared with only two (7%) of the control children, a significant difference. Eleven of those 22 children no longer qualified for the diagnosis a year later, and there was no significant difference between the frequencies of ADHD in the two groups. However, there was no significant association between measures of sleep-disordered breathing and either baseline or follow-up neurobehavioral morbidity.

The lack of an association could reflect inadequate sample size, the researchers said, but they noted that the sample size was more than sufficient to identify statistically significant postoperative changes in several other variables.

Another possibility is that standard measures of sleep-disordered breathing may not adequately assess the mild form of this condition that is common among children referred for adenotonsillectomy.

There is also the possibility that some correlate of sleep-disordered breathing, rather than sleep-disordered breathing itself, is the true cause of the neurobehavioral morbidity.

CRITICAL INSIGHTS INTO THE NATURE OF NICOTINE ADDICTION
A SUMMARY OF KEY LEARNINGS TO DATE

With all the public awareness efforts that have been made, and with all the truths that have come to light over the last several decades about the dangers of smoking, one obvious question lingers: Why are people still smoking?

Understanding nicotine addiction

Most experts agree at this point that smoking is a chronic, relapsing condition—an addiction similar in nature to that seen in cocaine and heroin users. Following are 4 criteria the Surgeon General has used to define addiction, along with an explanation of how nicotine—specifically smoking—meets these criteria:

1. Addiction leads to compulsive use, despite adverse consequences.

According to a 1988 Surgeon General’s report, “Highly controlled or compulsive use indicates that drug-seeking and drug-taking behavior is driven by strong, often irresistible urges. It can persist despite a desire to quit or even repeated attempts to quit.” Smoking statistics show that approximately 70% of current smokers report that they want to quit; however, only about 5% of smokers who try to quit without medical aid succeed. In fact, the average smoker has tried to quit 6 to 9 times. It is common for people to continue smoking despite known negative health consequences. In fact, smoking behavior often persists even after the presentation of comorbid conditions.

2. Addiction involves a psychoactive substance with reinforcing properties.

The psychoactive (mood-altering) properties of nicotine are substantially related to its effect on the mesolimbic dopaminergic system. For delivery of nicotine, smoking is the most efficient mechanism. In a matter of seconds, nicotine from inhaled smoke crosses the blood-brain barrier and begins altering brain chemistry through binding to cholinergic receptors normally activated by acetylcholine. Dopamine is released in the nucleus accumbens, triggering central nervous system effects such as pleasure, relief of anxiety, better task performance, and improved memory. These rewards serve to reinforce smoking behavior.

Complicating this effect is that the routines associated with smoking, such as smoking in social environments, can also come to reinforce the pleasure response. Eventually, the pleasure associated with smoking in these settings acts as a subconscious trigger, making it hard for the smoker to dissociate the behavior from the addiction. This explains why successful quit attempts often require some degree of behavioral modification.

3. The addicted subject develops tolerance.

Nicotine initiates its action by competitively binding at the nicotinic acetylcholine receptors (nAChRs), ligand-gated ion channels on the cell membrane. Compared with the endogenous agonist acetylcholine, nicotine causes a prolonged activation of nAChRs. The activation is followed by a desensitized state in which the receptors are unresponsive to agonists. This process has been compared to tripping a circuit breaker.

Chronic use of nicotine leads to chronic desensitization of nAChRs. As more nicotine is consumed, and more receptors become desensitized, the user experiences a diminished pleasure effect with each subsequent cigarette smoked. As the response decreases, increasing levels of nicotine are required to achieve a consistent, desired effect. These are defining characteristics of tolerance.
Mask Ventilation Failure: Know the Predictors

BY BRUCE K. DIXON
Elsivier Global Medical News

W hikers, when combined with cer-
tain other patient characteristics, impose proper airway manage-
ment in the surgical suite, according to a study of over 22,000 mask ventilation at-
tempts at the University of Michigan in Ann Arbor.

“If a bearded patient is overweight, there is a history of snoring, and can’t pass the jaw protrusion test, mask ventilation may be difficult or impossible and he should be asked to shave,” Dr. Sachin Kheterpal said in an interview.

The investigators launched the 2-year study using a 5-point scale to grade mask ventilation (MV) difficulty. “We used a prospective, observational study to iden-
tify cases of grade 3 MV (inadequate unstable ventilation, or requiring two providers to maintain saturation), grade 4 MV (impossible to ventilate), and difficult intubation,” they said. Grade 1 MV signi-
fies no difficulty, whereas a grade 2 situation is not as easy and may require the use of an oral or nasal airway. Dr. Kheterpal explained.

Of the 22,660 cases in which mask ven-
tilation was attempted, there were 313 episodes of grade 1 mask ventilation (1.4% of MV attempts) in adult patients, and 37 episodes (0.16%) of grade 4 MV, he said. In the grade 4 mask ventilation episodes, Dr. Kheterpal said they could not ventilate despite using an oral airway and having two providers present. “Despite all the tricks of the trade at our disposal, we still could not move air in and out of that patient without using a tube or laryngeal mask airway,” he said.

There were 84 cases (0.37%) of grades 3 or 4 MV with difficult intubation.

Statistical analysis revealed that the independent predictors of difficult MV included having a body mass index (kg/m²) of 30 or greater; having a beard, exhibiting a Mallampati class III or IV pharynx on airway examination, being older than 57 years; having a his-
tory of snoring; and being unable to protrude the jaw forward. Independent predictors of grade 4 MV included snor-
ing, and a hyoid-to-mentum distance shorter than 6 cm.

“The jaw protrusion test is one that his-
torically has been recommended by the American Society of Anesthesiologists. In the past we have not used this test at the University of Michigan and little data were available on its utility, other than the original studies,” said Dr. Kheterpal. The test involves jutting out the jaw so that the lower teeth protrude beyond the upper teeth, enabling the patient to bite his upper lip.

Only one other study in the literature has examined risk factors for difficult mask ventilation (DMV), Dr. Kheterpal said. In that study of 1,592 patients, investigators found that, in a general adult population, the reported incidence of difficult mask ventilation was 5%. DMV was reported more frequently when intubation was difficult and when anesthesiologists did not accurately pre-
dict difficult intubation via the preoperative visit. Five criteria—age older than 55 years, BMI greater than 26, lack of teeth, presence of a beard, snor-
ing history—were independent risk fac-

“We believed that more research is needed to be done to confirm that study’s results and to look at previously untaxed parameters, such as the jaw protrusion test,” Dr. Kheterpal said in an interview.

In any given practice, “about 1 in 50 pa-
tients coming to the operating room is going to be impossible to ventilate,” said Dr. Kevin K. Tremper, professor and chair of anesthesiology at the University of Michigan and a coauthor of the study. He added that most patients in that situation can still be intubated: “In our study pop-
lation, there was only one person in whom we could do neither and had to do a mask ventilation.”

The bottom line, according to Dr. Trem-
per: “If a surgery patient is obese, smokers, can’t protrude his jaw, and has to have a beard, he should be intubated at risk of a rare but serious problem and therefore should seriously consider shaving off the beard.”

References:


Critical Care Medicine

May 2006 • CHEST PHYSICIAN

9
Adenotonsillectomy Improved Kids’ Obstructive Sleep Apnea

BY ROBERT FINN

Elsevier Global Medical News

RANCHO MIRAGE, CALIF. — Children who undergo adenotonsillectomy for severe obstructive sleep apnea show significant decreases in heart rate and heart-rate variability, according to a poster presented at a conference on sleep disorders in infancy and childhood sponsored by the Annenberg Center for Health Sciences.

“Resolution of tachycardia and diminished pulse-rate variability after treatment of severe obstructive sleep apnea syndrome illustrates the stress that recurrent airway obstruction during sleep places on the cardiovascular system,” said Dr. Evelyn Constantin and colleagues from Montreal Children’s Hospital.

They also speculated that pulse rate and pulse-rate variability, as measured by pulse oximetry, may be useful in diagnosing obstructive sleep apnea syndrome (OSAS), especially in those children who do not show oxygen desaturation.

The study involved 26 children, aged 1-18 years, who were referred for adenotonsillectomy after exhibiting McGill oximetry scores of 3 or 4, indicating moderate or severe OSAS. The investigators excluded children who had congenital or genetic conditions; those with cardiorespiratory, neurologic, or neuromuscular conditions; and those with global developmental delay.

Postop home oximetry and parent questionnaires were completed in the months after the surgery. The average age of the children at surgery was 4.4 years, and at postop oximetry it was 4.8 years.

The surgery resulted in significant improvement in several measures of oxygen saturation. For example, the mean minimum saturation increased from 67% to 87%, and the number of falls in saturation at or below 90% decreased from 5.3 per hour to 0.2 per hour.

Following adenotonsillectomy, pulse rate decreased significantly in 21 of the patients (81%), and pulse-rate variability decreased significantly in 23 (88%). The mean pulse rate declined from 101 beats per minute (bpm) to 91 bpm, and the standard deviation of the pulse rate declined from 10 bpm to 8 bpm.

CPAP May Counter Sleep Apnea’s Cardiac Effects

BY MELINDA TANZOLA

Elsevier Global Medical News

People with severe obstructive sleep apnea have structural and functional cardiac changes, but these abnormalities may improve after treatment with a continuous positive airway pressure device, results of a recent study suggest.

“The implications of this study are profound, indicating OSA [obstructive sleep apnea] as a new primary cause of hypertension,” wrote study investigator Dr. Bharati Shivalikar of the University Hospital Antwerp (Belgium) and associates.

The researchers found right ventricular dilatation, left ventricular hypertrophy, and reduced function of both ventricles in 43 patients with severe OSA and significant daytime sleepiness. Mean apnea-hypopnea index (AHI), which indicates the number of episodes of hypopnea and apnea per hour of sleep, was 42. The patients had a mean body mass index of 31.6, inducing obesity. Six months after receiving CPAP treatment, individuals had significant improvements in apnea symptoms, hemodynamics, and ventricular morphology and function (J. Am. Coll. Cardiol. 2006;47:1433-9).

At baseline, patients with obstructive sleep apnea had a significantly higher mean resting blood pressure, compared with 40 age-matched, overweight controls (153/88 mm Hg vs. 132/78 mm Hg). Their mean resting heart rate was also significantly higher, at 77 vs. 68 beats per minute (bpm). Compared with controls, individuals with apnea had dilated right ventricles and thicker interventricular septa.

A total of 23 of the 43 patients were evaluated after 6 months of CPAP treatment. Several functional measures were significantly improved in these patients, including left ventricular ejection fraction and stroke volume, tissue Doppler-detemined systolic and diastolic velocities for the left and right heart, and right and left ventricular performance. Blood pressure dropped significantly from 159/92 mm Hg to 138/80 mm Hg after treatment. Heart rates declined significantly from 73 bpm to 67 bpm.

Multiple morphologic and functional cardiac measurements correlated significantly with AHI scores. The investigators identified three parameters—interventricular septum thickness, right ventricular free wall, and mitral annulus tissue Doppler systolic velocities—that significantly predicted a higher AHI score.

Dr. Susan M. Harding, FCCP, comments:

Although only 58% of subjects had 6-month follow-up, these data support the notion that 6 months of CPAP therapy improves blood pressure, heart rate, and left ventricular ejection fraction. The time is right to design and perform a multicenter trial examining cardiovascular outcomes with CPAP therapy.

Acetazolamide Improved HF-Related Central Apnea

BY MELINDA TANZOLA

Elsevier Global Medical News

A 6-night course of acetazolamide appeared to improve sleep-disordered breathing in a study of 12 men with heart failure–related central sleep apnea.

In central sleep apnea (CSA), respiration temporarily ceases because of a decline in partial pressure of carbon dioxide (PCO2) below the apneic threshold. However, in a study by Dr. Shahrokh Javaheri, FCCP, and his associates, the diuretic and respiratory stimulant acetazolamide seemed to reduce the likelihood of PCO2 crossing the apneic threshold by inducing a state of metabolic acidosis.

Although acetazolamide has been used in congestive heart failure for many years, there are no systematic studies regarding its effect on Cheyne-Stokes breathing,” said Dr. Javaheri of the University of Cincinnati.

In a randomized, double-blind, placebo-controlled study, Dr. Javaheri and associates evaluated acetazolamide in 12 male patients with stable heart failure with left ventricular systolic dysfunction and demonstrated CSA (Am. J. Respir. Crit. Care Med. 2006;173:234-7). For 6 nights, patients received either placebo or a single dose (3.5 mg/kg) of acetazolamide and 30 mEq of potassium chloride (to offset the urinary potassium loss caused by acetazolamide) 1 hour before their bedtimes. The acetazolamide dosage was increased to 4.0 mg/kg on the third day, to achieve a total CO2 decrease of 5 mmol/L. After a 2-week washout period, crossover studies were initiated.

The mean baseline frequency of central apnea was 44 episodes per hour. When patients were treated with acetazolamide, CSA frequency was 23 episodes/hour, compared with 49 episodes/hour when they received placebo. Arterial oxyhemoglobin saturation also improved significantly with acetazolamide, although other sleep-related and pulmonary measurements were similar between study arms.

Acetazolamide caused mild metabolic acidosis in the morning. One patient on the study who was on the cardiac transplantation list developed shortness of breath while on acetazolamide. No instances of parasthesias were noted.

Patients reported significant improvements in sleep quality, daytime fatigue, and other symptoms with acetazolamide.

“In spite of the short duration of the study and modest reduction in periodic breathing, patient perception improved,” the investigators noted. They hypothesized that long-term improvement in periodic breathing could, in turn, improve cardiac function.
Safety of Long-Acting Beta-Agonists: As Simple as Black or White?

Editor’s Insight

Perhaps, unfortunately, the SMART trial was not designed to evaluate the concurrent use of LABAs and inhaled corticosteroids, so we cannot really determine the role of the use of LABAs alone without concurrent inhaled corticosteroids as a factor in the increased risk observed in the African-American subpopulation. We do know, however, that racial disparities confound principles of care. Two-way biases permeate all patient and clinician interactions. Trust is key in the clinician-patient relationships, and it must be earned by the clinician. Effective communication skills and genuine clinician interest for the patient go a long way in reducing these barriers. Effective individualized, culturally sensitive communication allows patients to understand their asthma and its treatment.

The primary use of corticosteroid inhalers is key. LABAs should never be used as monotherapy (see Global Initiative for Asthma Guidelines at www.ginaasthma.com). It is essential that patients understand that increased frequency in the use of either long- or short-acting beta-agonists denotes worsening asthma that may be life-threatening and requires intervention. Education is critical.

—Deputy Editor

Two Questions

I would like to present two questions to underscore two important themes:

1. The following patient/family characteristics are reliably associated with the ability to adhere to your prescribed asthma therapeutic plan:
   A. Race
   B. Ethnicity
   C. Socioeconomic status
   D. Education level
   E. None of the above (A D)
   F. All of the above (A D)
   Correct answer: E. Contrary to popular medical belief, clinicians cannot predict better than chance which patients are adhering to the medical regimen. There are many different forms of nonadherence, all of which interrupt or interfere with the opportunity for therapeutic success.

2. Effective communication of asthma education is proven to create all of the following EXCEPT:
   A. Increased office visit times
   B. Improved patient/family self-efficacy
   C. Fewer asthma hospitalizations and emergency department visits
   D. Enhanced patient/family confidence that their concerns have been heard
   E. An opportunity to share significant concerns that may hamper adherence
   Correct answer: A. Even “established” clinicians can benefit from learning and refining communication skills, as most patients identify this to be an area where doctors could better their medical care. Specific physician communication techniques are shown to boost family confidence, augment patient self-efficacy, and improve asthma patient outcomes without adding additional time to the office visit.

Together (33% increase compared with the placebo group).

In their concluding remarks, the authors took note that the study’s “imbalance occurred largely in the African-American subpopulation.” Also, they wondered if the cause for the racial imbalance was due to “factors including, but not limited to, a physiologic treatment effect, genetic factors, or patient-level behaviors leading to poor outcomes (e.g., delay in seeking care, compliance with study treatments or asthma medications).”

What are the facts regarding this issue and do they really matter? Physiologic and genetic variability has, indeed, surfaced as a significant therapeutic issue in asthma.

Specifically, studies have described racial differences in corticosteroid response (Federico et al. Chest 2005; 127:571) and deleterious beta-adrenergic receptor changes that may be more prevalent in more at-risk populations (Drysdale et al. Proc Natl Acad Sci 2000; 97:19483).

In the randomized SMART study, it is doubtful, though, that the lower rates of corticosteroid use in African-Americans account for the entirety of the increased risks observed. Even Caucasian asthma-related deaths numbered 6 in the salmeterol group and 1 in the placebo group. However, as purely a sampling of usual asthma care in the United States, doesn’t this study’s inhaled corticosteroid discrepancy primarily underscore that unequal treatment with respect to “behaviors” is better labeled as “physician level”?

Asthma care variation and health-care disparities, in general, remain an area of deep concern in the United States (Institute of Medicine. Unequal Treatment, National Academy Press, 2002). The asthma morbidity and mortality burden is shouldered disproportionately by the Hispanic and African-American communities.

However, despite issues of access to and confidence in our health-care system varying greatly, we know that similar adherence rates exist across racial and ethnic lines (Balancing the Equation: Ending Disparities in Health Care Delivery. www.kaiser.org; Accessed December 2005).

Why, then, would the SMART study authors suggest divergent patient-level factors that include compliance only now appear in African-American (and not Caucasian) patients receiving salmeterol?

Excellence in medical treatment is of no worth if the patient does not take the medication as prescribed. Clinician communication and patient education are vital to a family’s compliance with the clinician’s recommendations.

Studies consistently show that less than 50% of patients adhere to daily medicalization regimens.

Furthermore, clinicians cannot predict better than chance which patients will be compliant. Compliance is not reliably associated with family income, parental education level, ethnicity, or race.

All patients require proper education communicated in a manner that builds self-confidence and encourages adherence to the asthma treatment plan (Clark et al. Acad Med 1995; 70:957).

A family’s ability to follow preventive or therapeutic recommendations is based on its health beliefs. These beliefs include the following: (1) the extent to which a patient feels susceptible to asthma; (2) the perceived seriousness to the patient’s own health; (3) the personal benefits vs. the costs of the recommended treatment plan; and (4) the degree of confidence with which they can carry out the requested actions.

Some families resist accepting the diagnosis of asthma because they believe the same crippling fate of a relative may await them or their children. Others may not perceive the disease to be a threat at all (e.g., “it’s like a cold”), hindering their ability to follow the treatment plan.

Often, families may be too embarrassed to share these beliefs if they feel their disclosure will make them appear foolish or uneducated.

Eliciting underlying fears about the diagnosis and/or treatment regimen may be as, if not more, important than prescribing the proper medicine.

Teaching our colleagues to discuss the safety profile of controller medications using as few medical terms as possible is important.

A conversation about inhaled corticosteroid therapy (with or without combination LABAs) and how these and other medications work to keep asthma “under control” can be both useful and reassuring.

Frank discussion, too, about the real and perceived risks of these medicines invites families to more openly share the concerns that limit their acceptance and implementation of the treatment plan.

Opportunity for questions reinforces the family’s belief that the clinician is listening and, therefore, has the information needed to make a good treatment decision.

Even in susceptible patient groups, proven educational strategies can be efficiently delivered via effective communication during scheduled primary care office visits without adding additional time to the encounter (Brown et al. Chest 2004; 126:369).

Despite its limitations, the SMART study clearly points to the pressing need for heightened attention paid to research in our most vulnerable asthma populations.

We are reminded, also, that inattentiveness to new potential dangers within medical therapeutics is ripe opportunity for increasing health-care disparity.

Clearly, we should watch this developing story with great interest and an eye on safety for all asthma patients.

Dr. Randall W. Brown, MPH
Research Director
Georgia Pediatric Pulmonology Assoc.,
Atlanta, GA
Adjunct Associate Professor
Health Behavior and Health Education
University of Michigan School of Public Health
Ann Arbor, MI

Dr. Deborah Shure, Master FCCP
Editor, Pulmonary Perspectives

Dr. Aymarah Robles, FCCP
Deputy Editor, Pulmonary Perspectives
NEWS FROM THE COLLEGE

PRESIDENT’S REPORT

2006: Our Most Successful Caucus

It seems to do most of my Presidential editorial writing in airports. It is a good use of idle time. While others enjoy the sport of arriving just before the door is closed, I would rather not chance missing my flight home, but that’s not the subject of this month’s column.

I am in Reagan National Airport, awaiting my return flight to Tampa after attending the 14th Annual ACCP Capitol Hill Caucus. It is a well-worn cliché, but the Caucus just gets better every year (and this year, as in others, it’s true).

I feel qualified to comment, as I have attended all but one of the caucuses. This year’s attendance, including ACCP staff, topped 100, which is more than double the attendance in 2005. Don’t miss coverage of the Caucus in this issue of CHEST.

I will begin and end this column by suggesting that you consider attending the 14th Annual Caucus in 2007. Credit for the fast-paced and educationally dense program goes to the Government Relations Committee, chaired by Dr. Larry C. Mohr, Jr., FCCP and the Health Affairs Division, headed by Lynne Marcus. This year, the Government Relations Committee decided to concentrate on two issues: the sustainable growth rate formula, more affectionately known as the “unsustainable growth rate” formula, and the critical care medicine workforce crisis.

The first afternoon of the Caucus was directed at providing attendees with background information on these issues. In addition, a consultant provided instruction on “how to lobby your elected official,” in anticipation of the planned Capitol Hill visits. The role-playing exercise was entertaining and proved valuable during the next day’s visits.

Our dinner speaker that evening was the US Surgeon General, Dr. Richard H. Carmona, MPH. If you ask any of the attendees about the highlights of the Caucus, I bet they mention the Surgeon General. He is about as personable as you can get, and he gave a spellbinding talk. The country’s health is in good hands with Dr. Carmona.

The next morning, through the assistance of Senator Bill Nelson of Florida, we were able to secure the very remarkable and historic Senate Caucus Room in the Russell Building (where the Watergate hearings were held). A very impressive list of House and Senate members (including Representative Stark, Senator Crapo, and Senator Clinton) dropped by to provide their views on our two main issues and on a few of their own.

That afternoon, attendees visited the offices of their Representative and Senator. More often than not, attendees met with staff, but, as we were reminded, “Do not underestimate the influence of staff on the views and votes of the members.” Sharing these experiences on the hill, during and after dinner, was among the favorite activities of many attendees.

As promised, let me close by encouraging you to attend the 2007 Capitol Hill Caucus. Participating in the democratic process and walking the Halls of Congress is both energizing and a lot of fun.

Inside the ACCP: CHEST Reaches Around the Globe

As the ACCP’s flagship publication, CHEST has and continues to reflect the interests of the ACCP membership.

CHEST is the official journal of the American College of Chest Physicians (ACCP) and is considered by many to be the top clinical journal in its multidisciplinary fields.

CHEST’s success is a result of 70+ years of dedicated leadership and vision by ACCP and the journal’s Editors in Chief (Table) and Editorial Board members.

Initially launched in 1935 under the name Diseases of the Chest by the American Federation of Sanitarians (which became the ACCP in 1937), the journal focused on educating physicians about tuberculosis, the leading lung scourge at the time. As the development of powerful antibiotics became the ACCP in 1937), the journal continued its focus to cover the multidisciplinary nature of chest medicine.

In 1970, under the leadership of Dr. Alfred Soffer, Master FCCP, the journal’s name was shortened to CHEST.

As the ACCP’s flagship publication, CHEST has and continues to reflect the interests of the ACCP membership.

Over time, it has evolved from a publication that focused on surgical interventions for TB to a multidisciplinary publication that covers pulmonary, critical care, sleep, thoracic surgery, cardiorespiratory interactions, and related disciplines.

The Journal’s vital statistics show it to be a leader in numerous ways.

CHEST has: (1) the highest regular annual circulation/readerhip (e.g., 20,450) of any respiratory or critical care journal in the world; (2) increasing annual manuscript submissions (from 2,080 in 1994 to 3,368 in 2005); (3) a steadily falling annual acceptance rate (from 43% in 1993 to 17% in 2005); (4) the second highest number of total citations of all respiratory journals; (5) an impact factor of 3.11 and rising; (6) increasingly high profile coverage in major media outlets each month; and (7) excellent financial performance, which helps to support many ACCP activities.

And because CHEST is financially stable and is committed to supporting the educational mission of the ACCP, this journal remains one of the least expensive medical specialty journals; this facilitates its accessibility to subscribers, libraries, and institutions around the globe.

CHEST is truly an international journal. Of its 3,368 submissions in 2005, 33% were from the US, 4% Canada; and 63%, the rest of the world. And of those accepted and published, 30% were US, 1% Canada, and 69% rest of the world.

In addition, it is distributed to more than 100 countries around the world and distributes special international editions translated into local languages in China, Italy, Mexico, Latin America, Spain, and Turkey, with more to come. There is also a special English edition distributed in India.

The online edition of CHEST, www.chestjournal.org, is hosted by HighWire Press, a division of the Stanford University Library Systems.

The online edition offers numerous technology enhancements that allow users and readers to search its vast archive and PubMed; link to articles in CHEST and other journals; download material to handheld devices; build an online “article archive” that puts online articles at their fingertips; download figures into PowerPoint for use in lectures or reports; and use many other useful tools.

CHEST is committed to increasing these enhancements in the future.

Under the current leadership of Editor in Chief Dr. Richard S. Irwin, FCCP, CHEST has already undergone significant changes and is poised to continue its push to be the most relevant and read journal in its multidisciplinary fields. We encourage our readers to give us feedback on the journal at any time and thank them for their support and suggestions.

Feedback can be sent to editor@chestnet.org.
May 2006 • CHEST Physician

Sleep Strategies

Tin Soldiers and Capped Rental Coming: New Regulations for CSA

For those of you who deal with durable medical equipment (DME), this may not be news to you. For those of you who deal with patients with central sleep apnea (CSA), the CMS change in the FSS category will even- tually impact you. The current FSS payment category will eventually disappear with the reclassification to the “capped rental” category. There are also new coverage criteria for patients with central sleep apnea (CSA). What does all this mean?

CMS published a final regulation in the Federal Register notice (http://as27.g.akamaitech.net/7/257/2422/0jma20661800/edocket.access.gov/2006/pdf/06-798.pdf) that would shift payment for all RADs with a backup rate (EO471) from the prior “FSS” to the “capped rental” category. Under the FSS payment schema, CMS paid out as long as the beneficiary required the device. With the “capped rental” payment plan, this continues for 13 months in a rent-to-own process (similar to what CSA) but minimal oximetry requirements and showing a “significant improvement” after 4 hours a night. This new set of criteria and definitions are actually retroactive to January 1, 2006, and can be viewed at the DMERC carrier Web site for your region and at the following Web site: www.palmettogba.com/palmetto/providers.nsf/(Docs)/85256D580043E75485256A6F0055769A?

With the endorsement of the ACCP and ATS, NAMDRG arranged a meeting on March 6, 2006, at the office of Senator Mike Crapo (R-ID). Chair of the Congressional COPD Caucus, in conjunction with representatives from the FDA, CMS, and Health and Human Services (HHS), Neil MacIntyre, MD, FCCP; Nick Hill, MD, FCCP, and I indicated concern that there is a wide variety of diseases and severity of condition for which patients are prescribed an EO471 device for home NIV, some of which need frequent reassessment of the patient ventilator interaction. As the discussion evolved, an effort was made to clarify that it is the application to the clinical condition that really determines what makes a device a “therapeutic ventilator,” as the RADs have been and are being used even on patients with a tracheostomy that all would agree makes the device a “therapeutic ventilator” by the CMS language used in the January 27, 2006, Federal Register cited above. The point was further emphasized that if you focus entirely on the device to describe the situation, it can lead to clinical and misleading presumptions about the therapy. Unfortunately, there is no true definition for the terminology of “therapeutic ventilator” or “respi- ratory assist device.” If decisions for servicing and payment remained focused on just the device, it is possible that clinicians might switch patients to more sophisticated and expensive home portable ventilators to obtain the FSS reimbursement for a higher care delivery result. Presumably, the manufacturers could also follow suit and alter the RADs to have more of an appearance of a “therapeutic ventilator.”

The conclusion of the meeting was to have HHS review this FSS issue with their General Counsel’s office and de- cide whether there is enough flexibility to revisit the interpretation of the present statute. We hope it will allow some reasonable clinical criteria to enter into the determination of a pa- tient’s reimbursement status and not depend solely on the device. If this is affirmed, then select members of the pulmonary/sleep community may be called upon to create criteria and patient scenarios. If there is a denial of this possibility, Senator Crapo is then committed to help solve the problem legislatively. The attendees decided 60 days would be a reasonable time frame for the General Counsel to respond and also allow plenty of time to create legis- lation before the first capped rental process is in effect, as the 13-month period comes up on May 1, 2007 (assuming that the regulation goes into effect on April 1, 2006).

A very advantageous alteration in the coverage criteria for patients with CSA was also announced with the above. The previous coverage criteria for CSA were burdened by the mandatory hypoxemia requirement restricting patients with major sleep disruption from CSA but minimal oxygen reduction to the sole option of CPAP. At the initiation of sleep specialists at the Mayo Sleep Disorders Center, a propos- al was brought forth to the three newly designated DME Regional Centers and DMEC directors, who now include Drs. Paul Hughes, Mark Pilley, and Adrian Oleck. As a result, a revised cover age position emerged, eliminating the in- appropriate oximetry requirements and also recognizing the problem encoun- tered when patients with qualifying ob- structive or mixed sleep apnea develop significant CSA when exposed to CPAP. The patients that develop new or very promi- nent CSA during CPAP titration are now designated as “complex sleep apnea” or CompSA. The new criteria only demand that the pa- tients have a facility-based polysomno- gram and receive a diagnosis of either (a) predominate (>50%) CSA with at least five events per hour, or (b) Comp- SA. They must fail the CPAP titration and show a “significant improvement” with an EO471 device, and, then, it can be prescribed. This can be a bilevel device with a backup rate or a newly approved ventilator (Adapt Servo Ventilator; Dr. Peter C. Gay, FCCP

Associate Professor of Medicine
Pulmonary Critical Care, and Sleep Medicine
Mayo Clinic, Rochester, MN

SLEEP STRATEGIES

September 15–16, 2006
American College of Chest Physicians
Northbrook, IL
Chair: Janet Maurer, MD, MBA, FCCP
Co-Chair: Nicola A. Hanania, MBBS, FCCP

Join a multidisciplinary team of investigators and clinicians to discuss the interplay of depression and anxiety in patients with COPD. New comprehensive measures of best practices standards and examination of patient care issues will promote understanding that will empower investigators to identify research needs and direct future studies. Clinicians to better diagnose and treat patients with COPD.

Attendee Goals:
- Review the prevalence of depression and anxiety in patients with COPD.
- Assess the accuracy of currently validated screening tools.
- Evaluate the efficacy of current therapies by integrating results from high-grade published studies.
- Identify the future research needed to improve diagnosis and management strategies.
- Disseminate the findings and recommendations to key audiences.

Register now for discounted fees. Online registration available at www.chestnet.org.

Collaborating To Advance Care.
Detection and Management of Depression and Anxiety in COPD: A Multidisciplinary Scientific Workshop
With the publication of Grading Strength of Recommendations and Quality of Evidence in Clinical Guidelines: Report From an American College of Chest Physicians Task Force,1 in the January 2006 issue of CHEST, the ACCP Health and Science Policy department has implemented a new grading system for guideline recommendations.

This system is based on the relationship between the strength of the evidence and the balance of benefits to risks and burdens (Table). In this simplified system, recommendations can be grouped into three levels: strong (grade 1) and weak (grade 2). If there is certainty that the benefits do (or do not) outweigh the risks, the recommendation is strong. If there is less certainty, or if the benefits and risks are more equally balanced, the recommendation is weak. Several important issues should be considered when classifying recommendations, including (1) the quality of the evidence that supports estimates of benefit and risk; (2) the importance of the outcomes of an intervention; (3) the magnitude and the precision of the estimate of the treatment effect; (4) the risk or burden of an intervention therapy; (5) the risk of the target event; and (6) patient values and preferences.

The strength of evidence is classified into three categories: high (grade A), moderate (grade B), and low (grade C), based on quality of the data abstracted from the literature. The strongest evidence comes from well-designed, randomized, controlled trials, with consistent and directly applicable results. Moderate, quality evidence is based on randomized, controlled studies, with limitations that may include methodologic flaws and/or inconsistent results. In some circumstances, consistent evidence from observational and other nonrandomized studies may also be included.

The weakest type of evidence comes from other types of observational studies, which, when used appropriately, can provide additional data. It should be noted that the ACCP Health and Science Policy Committee accepts the principle that most relevant clinical studies from peer-reviewed publications provide evidence, even though the quality of that evidence may vary. Therefore, the criteria for including and excluding studies should be explicitly explained in each clinical practice guideline.

The balance between the benefits and the harms, or the lack thereof, helps determine the strength of the recommendation. A greater certainty of the balance leads to a stronger recommendation. Patient and community preferences are important considerations in decision-making and, therefore, are factored into the grading process. For weaker recommendations, there may not be much consistency in patient preferences. For strong recommendations, patient values may be very much aligned.

This new grading system eliminates the potential for misinterpreting guideline recommendations by basing recommendations strictly on the strength of evidence and balance of benefits and harms. The Health and Science Policy Committee hopes to maintain consistency by implementing this method for all ACCP clinical practice guidelines. For more information, go to www.chestnet.org/education/guidelines/index.php.


### Improved Knowledge. Improved Care.

**Multidisciplinary Care of Thoracic Surgery Patients: Clinical Updates, Case Forums, and Hands-on Workshops**

August 25-27, 2006
Chicago, IL

Course Directors:
Jeffrey A. Hagen, MD, FCCP
David W. Johnstone, MD, FCCP

Join leading experts as you study and review the foundation you need for making effective treatment decisions. Hear updates and strategies that can help you enhance your patient care and lead to improved clinical outcomes.

- A patient-focused curriculum will allow you to apply the latest knowledge directly to your practice.
- A multidisciplinary approach will give you an understanding of how the teams can work together to improve patient care.
- A world-class faculty can address your specific questions.
- A comfortable learning environment, featuring hands-on workshops, will offer practical clinical experiences.

Register now for tuition discounts.
Online registration available at www.chestnet.org.

### ACCP Product Highlights: Online Education Site

The ACCP online education site opens the door to many educational opportunities. View the newest virtual symposium Webcast, with audio tracks and faculty presentations or monographs from the CHEST 2005 satellite sessions. There are several topics on PAF, such as “Topical Issues and Controversies in the Treatment of Pulmonary Arterial Hypertension,” and “The Changing World of Pulmonary Arterial Hypertension Therapies: A Focus on the Patient,” to list a few.

Education opportunities in asthma and COPD are also available. These are all CME opportunities for those who did not claim them for CME at CHEST 2005.

ACCP recognizes the importance of sleep medicine in the pulmonary community. An on-demand Webcast is available, featuring the latest clinical information for effective evaluation, diagnosis, and treatment of sleep apnea. This product includes three video presentations with slides from the 2006 ACCP Sleep Medicine Course and syllabus.

Check out our newest products in the ACCP online store: “Clinical Insight in Practice: COPD.” “Clinical Insight in Practice: Asthma,” and “Hypertensive Crisis: Strategies To Minimize End Organ Damage With Focus on the Heart and Brain.”

For more information, visit www.chestnet.org/education/online.
The 2006 Caucus welcomed its largest attendance in history, with participation from 80 ACCP members.

**First Attendee Impression**

"My first attendance at the ACCP annual Capitol Hill Caucus was a very insightful one. It gave me the opportunity to understand the complex interplay of political decision-making and the impact it has on the day-to-day care of our patients. I have come to realize that in order to make an impact in the decision making process with regard to our issues of interest, every member of the College needs to establish a relationship with his/her representative and campaign to meet our patients' needs. We need to make it our responsibility to keep our legislators continually informed of the issues that confront us and our medical perspective in political decision making."  

**An ACCP Governor Reports**

"As the Arizona Governor for the ACCP, I wanted to relay to all of you what the ACCP is doing on behalf of its members, which includes specialists in pulmonary, critical care, cardiology, and thoracic surgery and many allied health members.

The Capitol Hill Caucus was a very positive event in raising awareness of issues that are important to members of our College. I would encourage all of you to call or write your Representatives and Senators. The College offers you a software program called CapWiz that makes it very easy to send an e-mail to members in Congress. Go to the ACCP Web site (www.chestnet.org), and click on Practice Resources, then Government Relations, and enter your home zip code."

**Canadian Governors Enlightened**

"We were impressed with the presentations given by the Congressmen, Senators, and legislative staff, and the grasp of the issues that they displayed during the question and answer sessions. We appreciated the politicians' candor and willingness to disagree with us. Our medical system is very different, but Canadian respiratory physicians face many of the same problems, issues, and challenges. Hopefully, we will be able to apply the lessons learned in Washington to effectively advocate for the issues facing respiratory medicine in Canada. We will need to educate the legislators and the public in order to do so appropriately.

Our Capitol Hill experience will help us lobby for more support for innovative care at the provincial level and for more research support from the lung associations, non-profit organizations, and from both the provincial and federal governments. We will strongly encourage the Canadian governors to attend future Capitol Hill caucus meetings."
**News from the College**

**Affiliate NetWork**
The Affiliate NetWork Steering Committee is working on a number of activities for CHEST 2006. Submissions for case reports have been made, and the grading process is now underway.

The 2006 CHEST Challenge will provide affiliate members a chance to participate in the Jeopardy-style competition. Nine teams will be selected to participate in the final rounds at CHEST 2006. The teams selected will receive roundtrip airfare, hotel accommodations, and meeting registration. The winning team will be awarded $5,000. Participation is open to affiliate members currently in training. For more details, go to www.chestchallenge.org. We invite you to visit the NetWork Web page, at www.chestnet.org/networks/affiliate/index.php.

**Airways Disorders NetWork**
Inhaled beta-2-agonists have been used to treat asthma for more than 40 years. Long-acting beta-agonists (LABAs) provide sustained bronchodilation and improved asthma control when used in the long-term treatment of persistent asthma. However, the long-term safety of LABAs has recently been questioned. The SMART study (CHEST, January 2006) revealed a small, but statistically significant, increase in the incidence of adverse asthma and respiratory experiences in asthmatics. Currently, the Pulmonary-Allergy Drugs Advisory Committee of the Food and Drug Administration (FDA) require warnings that state, “These medicines may make asthma episodes more severe when they occur,” and the committee warns against their use in first-line asthma therapy, unless other medicines alone do not control the disease. This advisory conflicts with the current asthma treatment guidelines, creating confusion among health-care workers and patients. Studies are underway to determine the genetic variability in use of these drugs.

**Allied Health NetWork**
To make things happen in an area of need, the Allied Health NetWork has found that the best projects are those done in collaboration with other NetWorks. One such program is the Inhaled Aerosol Device Project. Arguably, the management of asthma and COPD is 10% medication and 90% education. Researchers report that between 23 and 68% of patients, who are prescribed aerosol devices, do not use them well enough to benefit from their use. This represents up to $7 billion health-care dollars wasted each year. To address this problem, the Allied Health NetWork joined forces with the Airways Disorders, Home Care, and Respiratory Care NetWorks to produce handouts that show how to properly use and maintain specific inhalers and nebulizers. Studies are underway to determine the genetic variability in use of these drugs.

**Cardiovascular Medicine and Surgery NetWork**
To make things happen in an area of need, the Allied Health NetWork has found that the best projects are those done in collaboration with other NetWorks. One such program is the Inhaled Aerosol Device Project. Arguably, the management of asthma and COPD is 10% medication and 90% education. Researchers report that between 23 and 68% of patients, who are prescribed aerosol devices, do not use them well enough to benefit from their use. This represents up to $7 billion health-care dollars wasted each year. To address this problem, the Allied Health NetWork joined forces with the Airways Disorders, Home Care, and Respiratory Care NetWorks to produce handouts that show how to properly use and maintain specific inhalers and nebulizers. Studies are underway to determine the genetic variability in use of these drugs.
Endothelin's Role in the Rapid Progression of Pulmonary Arterial Hypertension

Pulmonary arterial hypertension (PAH) is a devastating and rapidly progressing disease. Left untreated, PAH patients have an estimated 5-year survival rate of 34%.

**Increase in Endothelin**

Endothelin, a neurohormonal mediator produced by the endocardium, is overproduced in PAH. This excess endothelin is associated with dramatic structural changes in the pathology of PAH vasculature, including inflammation, vascular constriction, cell proliferation, and fibrosis.

**Origin of Vascular Injury**

Endothelin

**Two endothelin receptors mediate the effects of endothelin**

- ET<sub>A</sub>
- ET<sub>B</sub>

**Blockade of Both ET<sub>A</sub> and ET<sub>B</sub> Receptors Is Critical**

*Statements are based on observations reported from in vitro or animal trials.*

**To learn more about the effects of endothelin in pulmonary arterial hypertension, please visit**

www.endothelinscience.com
Second Critical Care Medicine Distinguished Scholar Award

All ACCP members who are active Fellows and board-certified in critical care medicine are invited to apply for the Second Eli Lilly and Company Distinguished Scholar in Critical Care Medicine award. Deadline for applications is May 31, 2006. The successful candidate is required to meet one or more of the goals established for the Second Distinguished Scholar in Critical Care Medicine. These goals include: (1) establish an identity for the diagnosis and management of diseases in a critical care environment; (2) promote alternatives for the treatment of critical care diseases; (3) educate patients about options for diagnosis and management; (4) educate and disseminate new knowledge about diagnosis and treatment within a critical care environment; and (5) address family, legislative, and regulatory issues and define new funding mechanisms leading to innovations and improvement in critical care. The successful candidate will serve for 3 years as the Second Eli Lilly and Company Distinguished Scholar in Critical Care Medicine and receive a stipend of $10,000 to develop a project. In the fourth year, a stipend of $10,000 will be given as honorarium or she serves in the role as mentor to the next Distinguished Scholar.

Go to www.chestfoundation.org and click on the Second Eli Lilly and Company Distinguished Scholar in Critical Care Medicine. Direct questions to Sue Ciezadlo at sciezadlo@chestnet.org.

Salt Lake City: Live It Up

Salt Lake City’s family-oriented attractions offer plenty of fun for adults and children throughout the day. When the sun sets, the fun heats up even more. Salt Lake City’s clubs and nightspots provide entertainment options from jazz and blues to country western line dancing to rock. Going out for drinks in Salt Lake City is just like going out anywhere in the US. Salt Lake City has bars, brewpubs, and restaurants that serve liquor 7 days a week. The only difference you may encounter is that some bars are considered private clubs and charge a nominal membership fee—$4 for a 2-or 3-week period—rather than a cover charge. Many restaurants and bars are located downtown, within walking distance of the Salt Palace Convention Center. If you want to venture farther, the easy-to-use TRAX light-rail service can take you where you want to go. With over 700 daily flights to Salt Lake City, it will be easy to get to CHEST 2006. International travelers may need a visa to enter the United States and should contact the US Immigration Department (www.usimmigration.org) or the US Customs & Border Protection (www.cbp.gov) for details. For more information, visit www.visitsaltlake.com.

National Critical Care Awareness And Recognition Month

The ACCP recommends its members and other dedicated professionals who care for critically ill patients. In honor of their efforts, May has been designated National Critical Care Awareness and Recognition Month. This observance acknowledges the dedication and commitment that critical care teams demonstrate while caring for patients and their families. The ACCP supports critical care professionals by offering relevant education and products, including courses and products throughout the year. Critical care is a primary focus at the annual CHEST meeting and is a featured curriculum topic area for CHEST 2006. In addition, The CHEST Foundation offers honor and research awards to recognize and fund projects that are advancing critical care.

The CHEST Foundation and the ACCP closely monitor critical care practices and actively develop programs to help improve patient care. The Critical Care Family Assistance Program is a groundbreaking program that offers educational and support resources to enhance communication in the ICU and to create better outcomes for everyone. Partnering with other professional societies to form the Critical Care Collaborative, the ACCP’s Critical Care Institute has joined forces with over 100,000 health-care professionals to help create new patient care models for the critically ill patient that will enable delivery of effective, efficient patient-focused care.

To view critical care resources available from the ACCP and The CHEST Foundation, visit www.chestnet.org or www.chestfoundation.org.
Postop Cognition Dip Tied to Inflammatory Markers

BY DOUG BRUNK
Elsivier Global Medical News

San Diego — Increased levels of C-reactive protein and other markers of postoperative inflammatory response were associated with neurocognitive decline following cardiac surgery, Dr. Basel Ramliaw stated at a congress sponsored by the Association for Academic Surgery and the Society of University Surgeons.

Dr. Ramliaw and his associates prospectively evaluated 41 patients who underwent coronary artery bypass graft and/or valve procedures that used cardiopulmonary bypass. The patients’ mean age was 67 years. All patients had neurocognitive testing preoperatively, postoperatively at day 4, and at 3 months. The validated took 45 minutes to administer and covered areas such as memory, executive function, naming, attention, fluency, and premorbid intelligence, said Dr. Ramliaw, who is with the division of cardiothoracic surgery at Harvard Medical School, in Boston.

The level of tau protein was increased 78% in patients with neurocognitive decline, compared with 29% in those without such declines.

Neurocognitive decline was defined as performing one standard deviation from baseline on at least 25% of tasks. Study participants also underwent serum testing preoperatively, again postoperatively at 6 hours, and again at 4 days. Levels of C-reactive protein (CRP) and of interleukin 1β, IL-6, and IL-10 were assessed, and an increase of serum tau protein after surgery was used as a marker of axonal central nervous system damage.

Of the 41 patients, 7 (17%) developed neurocognitive decline. Baseline characteristics and predictors of neurocognitive decline such as age, education level, and perioperative temperature did not differ significantly between patients with and without postoperative neurocognitive decline.

However, patients who experienced postoperative neurocognitive decline had significantly greater increases of CRP (11 IL-6, and IL-10) than those who did not.

In addition, the level of tau protein was increased 78% in patients with neurocognitive decline, compared with a tau protein level of 29% in their counterparts who did not show neurocognitive decline.

“There exists a significant association [between] the magnitude and persistence of the periperooperative inflammatory response and postoperative neurocognitive decline,” Dr. Ramliaw said. “This association is likely mediated by axonal damage.”

The incidence of neurocognitive decline decreased from 9% to 4% when surgery was delayed by 5 years after surgery, he said, adding that the etiology of this complication is not known. “It is likely a multifactorial problem.”

Dr. Ramliaw said, “Several theories have been advanced. The most obvious one is ischemia. Any microemboli might cause this.”

Other possible factors in neurocognitive decline include anesthesia, perioperative hypothermia, and low level of education.

“While there have been certain markers of brain injury following cardiopulmonary bypass, very few have been associated with successful neurocognitive de-

Dr. Ramliaw and colleagues provided important links between anesthetic mechanisms and with systemic inflammation.

---

INDEX OF ADVERTISERS

Action Pharmaceuticals US, Inc. 14-15

Astrazeneca 14-16

Boehringer Ingelheim Pharmaceuticals, Inc. 17-19

Elian Pharmacueticals, Inc. 11-12

Interus, Corp. 17

Pfizer Inc. 17-18

#5

MAY 2006 • CHEST PHYSICIAN

Cardiothoracic Surgery 19

---

Dr. Curt Sessler, FCPP, comments:
Postoperative cognitive dysfunction (POCD) is underdiagnosed and thus far remains somewhat of a mystery as to causative factors. However, some attempts have been made to delineate the etiology of POCD as advanced age, longer duration of surgery and anesthesia, cardiopulmonary bypass, infection, and pulmonary complications. This exciting work by Dr. Ramliaw and colleagues provides important links between anesthetic mechanisms and with systemic inflammation.

---

Dr. Basel Ramliaw, DO, comments:
Infection is not seen as a sole etiologic factor, but it is definitely an important factor. Infection has been shown to increase inflammatory markers such as CRP and IL-6. It is possible that the increase in inflammatory markers we observed are related to POCD.

---

Dr. Richard Levitan, MD, comments:
Infection certainly could lead to increased inflammatory markers, but it is not usually associated with a neurocognitive decline.

---

John R. Covino, MD, comments:
I believe that increased inflammation is a factor in neurocognitive decline. But we have to know what the etiology is. This study is certainly an important area for further research.